Envista Stock (NYSE:NVST)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$20.26

52W Range

$15.14 - $25.64

50D Avg

$19.27

200D Avg

$19.07

Market Cap

$3.51B

Avg Vol (3M)

$2.21M

Beta

1.31

Div Yield

-

NVST Company Profile


Envista Holdings Corporation, together with its subsidiaries, engages in the development, sale, and marketing of dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists, and periodontists under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, and Orascoptic brands; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Insignia, AOA, and Spark brands. This segment also offers software packages, which include DTX Studio Implant for treatment planning of dental implants; TX Studio Lab for prosthetics treatment planning; and DTX Studio Clinic to store and access a various clinical patient images. The company's Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, sensors, software, and other visualization/magnification systems; endodontic systems and related consumables; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

Show More

Industry

Medical - Instruments & Supplies

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

12,800

IPO Date

Sep 18, 2019

Website

NVST Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Equipment and Consumables$924.10M--
Specialty Products and Technologies$1.64B--
Consumables-$2.15B$2.07B
Equipment Sales-$421.60M$441.00M

Fiscal year ends in Dec 23 | Currency in USD

NVST Financial Summary


Dec 23Dec 22Dec 21
Revenue$2.57B$2.57B$2.51B
Operating Income$31.50M$319.20M$306.20M
Net Income$-100.20M$243.10M$263.50M
EBITDA$429.40M$484.40M$460.50M
Basic EPS$-0.60$1.51$1.63
Diluted EPS$-0.60$1.37$1.48

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Oct 30, 24 | 9:44 PM
Q2 24Aug 07, 24 | 10:35 PM
Q1 24May 01, 24 | 12:00 AM

Peer Comparison


TickerCompany
MMSIMerit Medical Systems, Inc.
COOThe Cooper Companies, Inc.
WSTWest Pharmaceutical Services, Inc.
ATRCAtriCure, Inc.
AKYAAkoya Biosciences, Inc.
HOLXHologic, Inc.
ATRIAtrion Corporation
ALCAlcon Inc.
RMDResMed Inc.
ANGOAngioDynamics, Inc.
HAEHaemonetics Corporation
ICUIICU Medical, Inc.
ATRAptarGroup, Inc.
TFXTeleflex Incorporated